Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pelitinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 20/20 | 1.00 |
| ▸ | ERBB2 | P04626 | 14/20 | 1.00 |
| ▸ | STK25 | O00506 | 1/20 | 1.00 |
| ▸ | CIT | O14578 | 1/20 | 1.00 |
| ▸ | CHEK1 | O14757 | 1/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | DAPK3 | O43293 | 1/20 | 1.00 |
| ▸ | JAK2 | O60674 | 1/20 | 1.00 |
| ▸ | STK17B | O94768 | 1/20 | 1.00 |
| ▸ | STK10 | O94804 | 1/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 1/20 | 1.00 |
| ▸ | ABL1 | P00519 | 1/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 1.00 |
| ▸ | FYN | P06241 | 1/20 | 1.00 |
| ▸ | FES | P07332 | 1/20 | 1.00 |
| ▸ | CSF1R | P07333 | 1/20 | 1.00 |
| ▸ | YES1 | P07947 | 1/20 | 1.00 |
| ▸ | LYN | P07948 | 1/20 | 1.00 |
| ▸ | MET | P08581 | 1/20 | 1.00 |
| ▸ | HCK | P08631 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pelitinib SCHEMBL29623744 | 1.00 | EGFR (1.00) | EGFRERBB2STK25CITCHEK1 | |
| Pelitinib SCHEMBL29352012 | 1.00 | EGFR (1.00) | EGFRERBB2STK25CITCHEK1 | |
| Pelitinib SCHEMBL93756 | 1.00 | EGFR (1.00) | EGFRERBB2STK25CITCHEK1 | |
| Pelitinib SCHEMBL29349785 | 1.00 | EGFR (1.00) | EGFRERBB2STK25CITCHEK1 | |
| Pelitinib SCHEMBL93757 | 1.00 | EGFR (1.00) | EGFRERBB2STK25CITCHEK1 | |
| SCHEMBL8132957 | 0.93 | EGFR (1.00) | EGFRERBB2STK25CITCHEK1 | |
| SCHEMBL6382792 | 0.93 | EGFR (1.00) | EGFRERBB2STK25CITCHEK1 | |
| SCHEMBL12641715 | 0.92 | EGFR (1.00) | EGFRERBB2STK25CITCHEK1 | |
| SCHEMBL10108217 | 0.92 | EGFR (0.85) | EGFRERBB2STK25CITCHEK1 | |
| SCHEMBL14944414 | 0.92 | EGFR (0.85) | EGFRERBB2STK25CITCHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 152 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747408-A1 | DIAGNOSTIC AND THERAPEUTIC METHODS FOR CANCER | GENENTECH, INC. (US) | 2026-05-27 | — | — | EP | disclosed |
| WO-2026102349-A1 | ANTI-INTERLEUKIN-23 RECEPTOR VHH ANTIBODIES AND USES THEREOF | GENENTECH, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20260124140-A1 | NON-FOULING OR SUPER STEALTH VESICLE | KAWASAKI INSTITUTE OF INDUSTRIAL PROMOTION (JP) | 2026-05-07 | — | — | US | disclosed |
| EP-4724813-A1 | MACROPHAGE SIGNATURES FOR DIAGNOSTIC AND THERAPEUTIC METHODS FOR LYMPHOMA | Genentech, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| EP-4709484-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | GENENTECH, INC. (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12522662-B2 | Anti-PD-L1 antibody, and preparation method therefor and application thereof | SYNBIO TECHNOLOGIES LLC (CN) | 2026-01-13 | — | — | US | disclosed |
| EP-4665735-A1 | KRAS INHIBITORS | Erasca, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| WO-2025245105-A1 | KRAS INHIBITORS | ERASCA, INC. (US) | 2025-11-27 | — | — | WO | disclosed |
| WO-2025226830-A1 | SHP2 AND EGFR INHIBITORS FOR THE TREATMENT OF CHORDOMA | ERASCA, INC. (US) | 2025-10-30 | — | — | WO | disclosed |
| EP-4618997-A1 | COMPOSITIONS AND METHODS FOR IMPROVED CANCER TREATMENT | The Council of the Queensland Institute of Medical Research (AU) | 2025-09-24 | — | — | EP | disclosed |
| WO-2022098638-A2 | DOSING FOR TREATMENT WITH ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES | GENENTECH, INC. (US) | 2022-05-12 | — | — | WO | disclosed |
| WO-2022098628-A2 | SUBCUTANEOUS DOSING OF ANTI-CD20/ANTI-CD3 BISPECIFIC ANTIBODIES | GENENTECH, INC. (US) | 2022-05-12 | — | — | WO | disclosed |
| WO-2022076462-A1 | DOSING FOR TREATMENT WITH ANTI-FCRH5/ANTI-CD3 BISPECIFIC ANTIBODIES | GENENTECH, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| US-20220115087-A1 | DIAGNOSTIC AND THERAPEUTIC METHODS FOR CANCER | GENENTECH INC (US) | 2022-04-14 | — | — | US | disclosed |
| WO-2022066805-A1 | TRICYCLIC PYRIDONES AND PYRIMIDONES | ERASCA, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
| CN-107794302-B | Method for determining responsiveness of cancer to epidermal growth factor receptor targeted therapy | 综合医院公司 | 2022-03-15 | — | — | CN | disclosed |
| WO-2022050954-A1 | DOSING FOR TREATMENT WITH ANTI-TIGIT AND ANTI-PD-L1 ANTAGONIST ANTIBODIES | GENENTECH, INC. (US) | 2022-03-10 | — | — | WO | disclosed |
| EP-3964513-A1 | COMBINATION PRODUCTS WITH TYROSINE KINASE INHIBITORS AND THEIR USE | Novartis AG (CH) | 2022-03-09 | — | — | EP | disclosed |
| EP-3962947-A2 | METHODS OF TREATING CANCER WITH AN ANTI-PD-L1 ANTIBODY | F. Hoffmann-La Roche AG (CH) | 2022-03-09 | — | — | EP | disclosed |
| WO-2022031749-A1 | DIAGNOSTIC AND THERAPEUTIC METHODS FOR LYMPHOMA | GENENTECH, INC. (US) | 2022-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124140-A1 | NON-FOULING OR SUPER STEALTH VESICLE | FUCA2, LNPEP, EEA1 | EGFR 746/4885ERBB2 988/4885STK25 3507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.